ArticleBlood advances2018

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.

James I Barnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.